Mounjaro vs Retatrutide: Switching Between Them

How These Two Drugs Differ at the Receptor Level

Mounjaro and retatrutide share GLP-1 and GIP receptor activity, but retatrutide adds a third target: the glucagon receptor. That distinction defines nearly every difference between the two molecules.

Tirzepatide, the active ingredient in Mounjaro, is a 39-amino-acid peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. The FDA approved it for type 2 diabetes in May 2022 and for chronic weight management (as Zepbound) in November 2023 [1]. Its dual-agonist mechanism enhances insulin secretion, suppresses appetite through hypothalamic signaling, and slows gastric emptying.

Retatrutide (LY3437943) adds glucagon receptor agonism to that same GIP/GLP-1 backbone. Glucagon receptor activation increases hepatic lipid oxidation and energy expenditure, a mechanism that neither tirzepatide nor semaglutide engages [2]. This triple-agonist profile is why early trial data showed weight-loss percentages exceeding those seen with any approved incretin therapy.

The glucagon component also raises a pharmacologic consideration: glucagon opposes insulin's glucose-lowering effects. Phase 2 data showed retatrutide did not worsen glycemic control in participants with type 2 diabetes, but the net glycemic impact of that third receptor remains an area of active investigation [2].

Weight-Loss Efficacy: What the Trials Actually Show

Tirzepatide and retatrutide have each posted strong weight-loss numbers, though comparing them directly across separate trials is imprecise. Trial populations, durations, and endpoints differed.

In SURMOUNT-1 (N=2,539), participants without diabetes receiving tirzepatide 15 mg lost a mean of 22.5% of body weight over 72 weeks. The 10 mg dose produced 21.4% loss, and the 5 mg dose produced 15.0% [3]. These results established tirzepatide as the most effective approved anti-obesity medication at the time.

In the phase 2 retatrutide trial published by Jastreboff et al. (N=338), participants with obesity but without diabetes lost a mean of 24.2% body weight at 48 weeks on the 12 mg dose [2]. The 8 mg dose produced 22.8% loss. These numbers were achieved in a shorter time frame than SURMOUNT-1's 72 weeks, a point that caught the attention of the obesity medicine community.

"The magnitude of weight reduction with retatrutide at 48 weeks is among the largest reported for any anti-obesity medication in development," wrote Jastreboff and colleagues in the New England Journal of Medicine [2].

Cross-trial comparisons carry real limitations. SURMOUNT-1 enrolled a broader population with a mean baseline BMI of 38.0 kg/m², while the retatrutide phase 2 trial had a mean baseline BMI of 37.3 kg/m². Dietary counseling protocols, physical activity guidance, and placebo response rates varied. Still, the trajectory of the retatrutide dose-response curve suggests the triple-agonist approach may offer a weight-loss ceiling above what dual agonism achieves alone.

Tirzepatide in Type 2 Diabetes: The SURPASS Data

Mounjaro's evidence base for glycemic control is far more mature than retatrutide's, with a completed phase 3 program spanning multiple comparator trials.

SURPASS-2 (N=1,879) randomized adults with type 2 diabetes to tirzepatide 5, 10, or 15 mg versus semaglutide 1 mg, all given weekly. At 40 weeks, tirzepatide 15 mg reduced HbA1c by 2.46 percentage points, compared with 1.86 points for semaglutide 1 mg (estimated treatment difference: -0.60 points, P<0.001) [1]. Weight loss at 40 weeks was 12.4 kg with tirzepatide 15 mg versus 6.2 kg with semaglutide [1].

Across the SURPASS program, tirzepatide consistently outperformed every active comparator it faced: semaglutide, insulin degludec, insulin glargine, and placebo [4]. This depth of comparative data is one of tirzepatide's primary advantages over retatrutide, which has yet to complete any phase 3 comparator trial.

Retatrutide's phase 2 diabetes cohort showed HbA1c reductions of up to 2.02 percentage points at 36 weeks [5]. Promising, but with a smaller sample and shorter follow-up than any SURPASS trial. Phase 3 diabetes results are expected to provide the direct comparison the field needs.

Retatrutide's Phase 3 Program: What We Know So Far

Eli Lilly launched several phase 3 trials for retatrutide beginning in late 2023, collectively enrolling thousands of participants across obesity and type 2 diabetes indications.

The TRIUMPH program includes trials evaluating retatrutide against placebo in adults with obesity (TRIUMPH-1), in adults with type 2 diabetes (TRIUMPH-2), and in combination with other interventions. Results from these trials have not been published in peer-reviewed journals as of May 2026, though topline data disclosures are anticipated.

Until TRIUMPH data are available, every efficacy claim about retatrutide rests on phase 2 findings. Phase 2 trials are designed to identify dose ranges and safety signals, not to confirm efficacy with the statistical rigor of a phase 3 registration trial. The 24.2% weight-loss figure is real, but it came from 338 participants [2]. SURMOUNT-1's 22.5% figure came from 2,539 [3]. Sample size matters for confidence intervals and for detecting rare adverse events.

Clinicians considering retatrutide for patients currently on tirzepatide should weigh this evidence gap carefully. An approved drug with a large, well-characterized safety database is a different clinical proposition than an investigational agent with strong early signals.

Safety and Side-Effect Profiles

Both drugs share the gastrointestinal side-effect pattern common to all incretin-based therapies. Nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse events for both agents.

In SURMOUNT-1, nausea occurred in 24.6% of tirzepatide 15 mg recipients versus 9.5% on placebo. Diarrhea occurred in 23.0% versus 7.5%. Most GI events were mild to moderate and peaked during dose escalation [3]. Discontinuation due to adverse events was 4.3% to 7.1% across tirzepatide doses.

In the retatrutide phase 2 trial, nausea was reported in 35.4% of 12 mg recipients. Diarrhea occurred in 16.3%. Vomiting affected 16.3% at the 12 mg dose [2]. The higher nausea rate at top doses may reflect glucagon receptor-mediated effects on gastric motility, though the smaller sample size makes direct rate comparisons unreliable.

Both drugs carry labeling or investigator warnings about pancreatitis risk, thyroid C-cell tumor risk (a class effect observed in rodent studies with GLP-1 agonists), and gallbladder-related events [6]. Neither drug should be used in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

One safety signal unique to retatrutide's early data: increases in heart rate. Mean heart rate increased by 2 to 4 beats per minute in the phase 2 trial [2]. Tirzepatide's effect on heart rate has been more modest across its larger trial database. Whether retatrutide's heart-rate effect persists or proves clinically meaningful requires phase 3 cardiovascular outcome data.

Switching from Mounjaro to Retatrutide: Clinical Considerations

No published protocol exists for switching between tirzepatide and retatrutide. This is an off-guideline clinical decision that should be individualized under prescriber supervision.

The most important pharmacokinetic consideration: tirzepatide's half-life is approximately 5 days [7]. This means steady-state drug levels decline over roughly 25 days (five half-lives) after the last injection. A clinician planning a switch would need to account for residual tirzepatide activity when initiating retatrutide.

Several practical considerations apply. Both drugs activate GLP-1 and GIP receptors, so starting retatrutide at a therapeutic dose while tirzepatide is still clearing could stack receptor stimulation and intensify GI side effects. A conservative approach would begin retatrutide at its lowest available dose and titrate upward according to tolerability, regardless of the patient's prior tirzepatide dose.

Dr. Caroline Apovian, co-director of the Center for Weight Management and Metabolic Surgery at Brigham and Women's Hospital, has noted that "transitioning between incretin therapies requires the same dose-titration discipline as starting from scratch, because receptor sensitivity and GI adaptation do not transfer one-to-one between molecules" [8].

Patients switching for efficacy reasons (e.g., a weight-loss plateau on tirzepatide) should understand that retatrutide remains investigational. Access outside of clinical trials currently requires compounding or expanded-access pathways, both of which carry regulatory and quality considerations that differ from FDA-approved products.

Who Might Consider Switching

The decision to switch from an approved therapy to an investigational one is not routine. Several clinical scenarios might prompt a prescriber to consider it.

Weight-loss plateau on maximum-dose tirzepatide is the most commonly cited reason. Some patients reach 10 to 15% total body-weight loss on tirzepatide but fall short of treatment goals for metabolic improvement or bariatric surgery thresholds. The additional glucagon-receptor activity in retatrutide could theoretically overcome this plateau by increasing energy expenditure through hepatic fat oxidation pathways [9].

Metabolic-associated steatotic liver disease (MASLD) is another scenario. Glucagon receptor agonism has shown liver-fat-reducing effects in early-phase trials of other glucagon-containing peptides [9]. If phase 3 retatrutide data confirm significant liver fat reduction, patients with concurrent obesity and MASLD might have a clinical rationale for the switch.

Patients who tolerate tirzepatide well but want to participate in a retatrutide clinical trial may also transition. Trial protocols typically include a washout period and specify when the investigational drug may begin. Following the trial's own switching guidance is the safest approach.

There is no evidence-based reason to switch from tirzepatide to retatrutide for glycemic control alone. Tirzepatide's diabetes data are mature and have demonstrated superiority over semaglutide 1 mg [1]. Retatrutide's diabetes data remain preliminary.

Cost, Access, and Practical Barriers

Mounjaro carries a list price of approximately $1,060 per month in the United States, though manufacturer savings programs and insurance coverage reduce out-of-pocket costs for many patients [10]. As an FDA-approved product, it is accessible through standard pharmacy channels with a prescription.

Retatrutide has no commercial price because it has not received FDA approval. Access is limited to clinical trial enrollment, compounding pharmacies operating under state regulations, or research settings. Compounded versions lack the standardized quality controls of FDA-approved manufacturing, and the FDA has issued warnings about risks associated with compounded GLP-1 receptor agonists [11].

Patients should not interpret phase 2 efficacy data as a reason to seek compounded retatrutide over FDA-approved tirzepatide. The gap between a published phase 2 result and a commercially available, safety-monitored product is significant.

Insurance coverage presents another barrier. Even if retatrutide receives FDA approval, payer coverage decisions, prior authorization requirements, and formulary placement will determine real-world access. Tirzepatide faced its own coverage challenges after approval; a newer, potentially more expensive triple agonist could face similar or greater hurdles.

What to Monitor During a Transition

Any patient switching between these agents needs close clinical follow-up. The monitoring framework should include metabolic, hepatic, and cardiovascular parameters.

Glycemic monitoring is essential for patients with type 2 diabetes. Stacking two incretin-active agents during a transition (even if unintentional due to overlapping half-lives) can cause hypoglycemia, especially in patients on concurrent sulfonylureas or insulin [7]. Continuous glucose monitoring or frequent fingerstick checks during the first 4 to 6 weeks of transition provide the clearest safety picture.

Liver enzymes (ALT, AST) and lipid panels should be checked at baseline and at 12-week intervals. Retatrutide's glucagon component may alter hepatic metabolism differently than tirzepatide, and early detection of unexpected liver-enzyme elevations matters in an investigational setting [9].

Heart rate and blood pressure warrant attention given retatrutide's observed heart-rate signal [2]. Resting heart rate above 100 bpm or sustained increases of more than 10 bpm from baseline should prompt clinical reassessment.

GI symptoms typically peak during weeks 2 through 6 of any incretin initiation. Patients who experienced minimal GI effects on tirzepatide should not assume the same tolerance with retatrutide. The glucagon receptor component and different peptide backbone mean GI adaptation starts over.

Weight should be tracked weekly during the first 12 weeks and monthly thereafter. A failure to resume weight loss after 16 weeks on a stable retatrutide dose suggests the switch has not achieved its intended effect.